Considering that the antibodies used in these studies, although different from one another, were all well controlled for the detection specificity, these studies suggest that alternative splice variants and/or posttranslational modifications of IDO protein in GBM samples may result in antigenic variations, and thus the dichotomous findings of IDO in GBM. The gene discussed is IDO1; the disease is glioblastoma.